Approval

Approval  ·  Weekly Digest - 20 December to 26 December 2025
Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Weekly Digest – December 2025 Weekly Digest – December 2025 25 December 2025: Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 20 December to 26 December 2025
GSK Korea, first approval of multiple myeloma treatment ‘Blenrep’ ADC

Weekly Digest – December 2025 Weekly Digest – December 2025 23 December 2025: GSK Korea, first approval of multiple myeloma treatment ‘Blenrep’ ADC GSK Korea received regulatory approval from Korea’s Ministry of Food and Drug Safety for Blenrep (Belantamab mafodotin), […]

by Sandhya Ramalingam

Continue Reading